I believe that with respect to Normal Saline the "Poison is in the Dose". I propose that the negative results of the SPLIT study was because minuscule amounts of fluid were given. This becomes relevant in the design of the definitive study. It wold be important a priori to subgroup patients according to the volume of fluid given and the severity of illness.
REVIEWER

Shailesh Bihari Flinders Medical Centre and Flinders University REVIEW RETURNED
04-Jun-2017
GENERAL COMMENTS
Well written protocol for a pilot randomized control trial of fluids (low and high chloride) in patients with septic shock. Main outcomes are consent rate, recruitment rate and the protocol adherence.
Study methodology is well explained and adequately discussed My only suggestion is to also consider the sodium load with the study protocol as generally less chloride also means less sodium which may have additional advantages
REVIEWER
Faheem Guirgis
University of Florida College of Medicine, Jacksonville, FL USA REVIEW RETURNED 04-Jun-2017
GENERAL COMMENTS
Summary -Very well done design for a clinical trial poised to answer the question of whether high concentration chloride fluids are detrimental to clinical outcomes in patients with septic shock. See main comments below.
Background Nice summary, though I believe the authors have left out one important study which makes their point, the JAMA paper by Yunos et al, a quasi-experimental study which showed benefit (improvement in RIFLE criteria) to removing high chloride solutions from their ICU Line 28 -stating that the patients in the trial by Young et al were "not that sick" is not very objective, perhaps a more quantitative measure of the acuity of the patients in that study would be more appropriate MethodsDesign -no issues PopulationWhy isn"t SOFA score included as an enrollment criteria? -given the recent update of Sepsis definitions I think using a minimum SOFA score (perhaps >=2) might be more in-line with the overall direction of sepsis research -I would encourage that this be included unless it is too late Informed consent -I applaud their use of modified delayed consent Experimental Procedures -robust; excellent accounting for the quantity of chloride in the colloids Blinding -no issues; one question -is there any concern that clinicians will be able to tell which fluid the patient received when they send a blood chemistry and see that the patient is hyperchloremic? Is there any potential remedy to this? Protocol Adherence -is there preliminary data to support the use of 75% study fluids to rule in protocol adherence? Clinical outcomes -I think it will be crucial to make sure that the renal outcomes in this study are sensitive enough to detect a difference between the groups. This was an issue encountered in the VANISH trial with regards to the dichotomous outcomes chosen in that trial. In this study, the authors mention the proportion of patients with RIFLE class renal failure, but will they look at change in category by RIFLE as well or perhaps change in absolute creatinine (though we know creatinine is an imperfect outcome)? Perhaps this would be more sensitive.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1
Jean-Pierre Quenot CHU Dijon, France
Please state any competing interests or state "None declared": None
leave your comments for the authors below
The question raised by the authors relates to the potential of chloride in the occurrence of acute renal failure and mortality, and remains a controversial topic because of the lack of data in the literature. The authors wish to start with a feasibility study to test compliance among clinicians with a protocol testing two crystalloids, which seems to be a good and timely idea, because it's one of the criticisms most often levelled at existing published studies on the subject.
The rationale and hypothesis, as well as the proposed methodology are all suitable for the aims, which are also clearly outlined.
The time window allowed for inclusions may be a little bit short, but takes account of existing international recommendations for the management of patients presenting circulatory arrest, which must be optimal within the first 6 hours after onset of symptoms.
We will all undoubtedly be impatient to see the results of this study. 
Please leave your comments for the authors below Few Minor Points:
Exclusion Criteria. Chloride poor solutions have a lower osmolarity than serum and therefore have the potential to increase cerebral edema in certain situations. For this reason I would exclude recent (? 7 days) ischemic stroke and recent Traumatic brain injury (regardless of the ICP).. see SAFE study **Thanks for this suggestion. We are not aware of any conclusive direct data suggesting a harmful effect of chloride poor solutions in the setting of ischemic stroke or TBI. Given the pathophysiologic rationale and indirect evidence, the FISSH steering committee did decide to exclude those with signs or symptoms of high ICP. In order to maximize pragmatism and avoid being too prescriptive, we decided to avoid broadening this exclusion criterion. However, as with all eligible patients, if the treating clinician decides there is not equipoise in a specific patient or they are uncomfortable randomizing then the patient will obviously be excluded. We are tracking these occurrences in the pilot phase and if we find that these subtype of patients are commonly excluded by the treating physician then we can always reconsider the criteria for the full trial.
I believe that with respect to Normal Saline the "Poison is in the Dose". I propose that the negative results of the SPLIT study was because minuscule amounts of fluid were given. This becomes relevant in the design of the definitive study. It wold be important a priori to subgroup patients according to the volume of fluid given and the severity of illness. **We couldn"t agree more and this was the motivation behind focusing on the high risk subgroup of patients with septic shock. Even still there is likely to be heterogeneity in amount of fluid received and we will consider this a priori subgroup in the definitive trial. Unfortunately in this pilot study we will not have ample numbers for any subgroup analysis.
Flinders Medical Centre and Flinders University
Please state any competing interests or state "None declared": None declared
-------------------------------------------------------------Please leave your comments for the authors below
Study methodology is well explained and adequately discussed
My only suggestion is to also consider the sodium load with the study protocol as generally less chloride also means less sodium which may have additional advantages **Thanks. Although we don't explicit mention chloride load in the protocol we may consider this variable (and we can add sodium load) in examining the difference between groups during the study period.
In effect this will demonstrate that there is separation between groups in terms of amount of chloride administered. This will be more important in the larger RCT than the pilot trial which is only focusing on feasibility outcomes. As such, we have not made any modifications to the protocol based on this comment but will consider it in the future FISSH full RCT. Also of note, we are capturing daily serum electrolytes (including sodium and chloride) in all study patients.
-------------------------------------------------------------
Reviewer: 4
Faheem Guirgis
University of Florida College of Medicine, Jacksonville, FL USA Please state any competing interests or state "None declared": None
-------------------------------------------------------------
Please leave your comments for the authors below Summary -Very well done design for a clinical trial poised to answer the question of whether high concentration chloride fluids are detrimental to clinical outcomes in patients with septic shock. See main comments below.
Background
Nice summary, though I believe the authors have left out one important study which makes their point, the JAMA paper by Yunos et al, a quasi-experimental study which showed benefit (improvement in RIFLE criteria) to removing high chloride solutions from their ICU **We have added this study to the background section as suggested by the reviewer. This sentence reads, "A before-and-after single center observational cohort study showed a decrease in renal failure in patients receiving low chloride fluids compared to high chloride."
Line 28 -stating that the patients in the trial by Young et al were "not that sick" is not very objective, perhaps a more quantitative measure of the acuity of the patients in that study would be more appropriate **Revised as suggested. The sentence now reads (revised section underlined), "…however, patients had low APACHE II scores (mean 14.1), received only a small amount of study fluid (median 2 litres throughout the trial period) and this pilot trial was underpowered to detect modest treatment effects"
Methods -
Design -no issues
PopulationWhy isn"t SOFA score included as an enrollment criteria? -given the recent update of Sepsis definitions I think using a minimum SOFA score (perhaps >=2) might be more in-line with the overall direction of sepsis research -I would encourage that this be included unless it is too late **Thanks for this suggestion and this consideration was discussed at length prior to study initiation. As the reviewer is aware generating the SOFA score requires capturing some blood test variables which are often not immediately available. Given the short time window for study enrolment (desired to avoid upfront contamination), we tried to make the enrolment criteria as clinical as possible. We are calculating daily SOFA scores for all admitted patients (including day 1) so will be sure to analyze this data from the pilot to ensure we are in fact capturing the patients we want (those with evidence of organ hypoperfusion).
Informed consent -I applaud their use of modified delayed consent **Thank you. This study would not have been possible without the ability to use deferred consent.
Experimental Procedures -robust; excellent accounting for the quantity of chloride in the colloids Blinding -no issues; one question -is there any concern that clinicians will be able to tell which fluid the patient received when they send a blood chemistry and see that the patient is hyperchloremic? Is there any potential remedy to this? **This is definitely a possibility. Although possible on day 1, depending on the volume of fluid administered, it is more a concern by study day 2 or day 3 that clinicians may be able to discern study arm based on serum chloride results. That being said, we are not certain this will be the case. Even still we believe the benefits of blinding are substantial, especially when it comes to differential administration of co-interventions (likely most relevant in the first 24-48hrs of the study). We did consider blinding patient chloride results to the treating team but had issues with operationalization and decided it was not worth the resources/cost given above.
Protocol Adherence -is there preliminary data to support the use of 75% study fluids to rule in protocol adherence? **This threshold was chosen based on feedback from the steering committee and examining protocol adherence thresholds for other complex interventions being investigated by CCCTG investigators. Based on the reviewers comment and to increase transparency we have added reference to this in the manuscript, it now reads, "This threshold was chosen based on discussion within the steering committee and after examining other pilot studies of complex interventions [9, 10] ."
Clinical outcomes -I think it will be crucial to make sure that the renal outcomes in this study are sensitive enough to detect a difference between the groups. This was an issue encountered in the VANISH trial with regards to the dichotomous outcomes chosen in that trial. In this study, the authors mention the proportion of patients with RIFLE class renal failure, but will they look at change in category by RIFLE as well or perhaps change in absolute creatinine (though we know creatinine is an imperfect outcome)? Perhaps this would be more sensitive.
**Thanks for this suggestion. We are capturing daily creatinine in our daily data set and will consider including this as a secondary outcome for the full RCT.
We are grateful for the opportunity to improve the presentation of our work and hope that we have addressed the suggestions and concerns raised through the peer-review and editorial review process. 
REVIEWER
Faheem Guirgis
University of Florida, Jacksonville REVIEW RETURNED 24-Jun-2017
GENERAL COMMENTS
They have satisfied all of my comments
